Oxford Cancer Biomarkers appoints Kathryn Kuhne as its Commercial and Marketing Director
Oxford, UK, 10 June 2016 Oxford Cancer Biomarkers has appointed Kathryn Kuhne as Commercial and Marketing Director, a key growth milestone for the company which aims to benefit cancer patients through developing molecular diagnostic tests that allow improved treatment decisions.
Oxford Cancer Biomarkers uses its molecular insights into disease and pathological processes to develop innovative diagnostic tests. “We are delighted to welcome Kathryn Kuhne to Oxford Cancer Biomarkers”, said Nick La Thangue, acting CEO. “Her past experience in driving profitable business growth through strong leadership with a strategic, innovative solution focussed approach will be particularly relevant as the Company expands to achieve substantial growth over the coming years through market launch and commercialisation of its proprietary diagnostic tests”.
Kathryn has 28 years’ experience within the pharmaceutical industry, 21 of which have been focussed within the oncology arena. She has been involved in the initial launches of 5 cancer drugs that changed the treatment pathways in colorectal, renal, prostate, liver, thyroid and breast cancers. During this time Kathryn has worked as a key account manager, key opinion development manager, market access manager, business development manager and national sales manager with companies Bayer, Sanofi-Aventis, Roche and Astellas.
Kathryn commented: “I am privileged to be joining Oxford Cancer Biomarkers at this exciting and important stage of its development. The company has huge potential – providing much needed diagnostic tests in the colorectal cancer arena. The tests align to the NHS 5 year forward view strategy, improving patient quality of life and securing cost effectiveness within the patient pathway for the NHS and private markets.
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.
For more information, please visit: http://www.oxfordcancerbiomarkers.com
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman